INmune Bio Inc.

NasdaqCM:INMB Stock Report

Market Cap: US$64.4m

INmune Bio Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of INMB?
Owner TypeNumber of SharesOwnership Percentage
Public Companies00%
Hedge Funds1,454,4005.24%
Individual Insiders2,999,28410.8%
Institutions4,369,46115.7%
General Public18,930,64468.2%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 29.1% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
5.47%
Mark Lowdell
1,518,017US$3.5m0.48%no data
5.24%
Highbridge Capital Management, LLC
1,454,400US$3.4m0%0.2%
4.67%
David Moss
1,294,883US$3.0m0.7%no data
2.92%
Vanguard Capital Management, LLC
811,199US$1.9m0.12%no data
2.3%
AQR Capital Management, LLC
639,555US$1.5m151%no data
1.12%
BlackRock, Inc.
311,613US$722.9k-73.9%no data
0.77%
Raymond James Financial, Inc.
212,995US$494.1k4.8%no data
0.69%
Geode Capital Management, LLC
190,215US$441.3k-61.6%no data
0.57%
Millennium Management LLC
159,559US$370.2k0%no data
0.57%
Susquehanna International Group, LLP
158,452US$367.6k-18.5%no data
0.48%
Jane Street Group, LLC
134,232US$311.4k163%no data
0.44%
Goldman Sachs Asset Management, L.P.
122,796US$284.9k19.3%no data
0.4%
UBS Asset Management AG
110,413US$256.2k-56.4%no data
0.39%
Westside Investment Management, LLC
108,300US$251.3k0%0.03%
0.38%
Citadel Advisors LLC
106,231US$246.5k0%no data
0.34%
State Street Investment Management
93,363US$216.6k-67.9%no data
0.31%
Scott Juda
86,404US$200.5k20.7%no data
0.3%
Hudson River Trading LLC
84,358US$195.7k0%no data
0.3%
IEQ Capital, LLC
82,385US$191.1k235%no data
0.3%
Timothy Schroeder
82,187US$190.7k0%no data
0.3%
GSA Capital Partners LLP
81,991US$190.2k0%0.01%
0.27%
Virtu Financial, Inc.
75,212US$174.5k0%0.01%
0.23%
The Goldman Sachs Group, Inc.
62,449US$144.9k-51.5%no data
0.19%
Laird Norton Tyee Trust Company
52,000US$120.6k4%no data
0.16%
Focus Advisor Solutions, LLC
43,556US$101.1k1.23%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/23 18:36
End of Day Share Price 2026/08/21 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

INmune Bio Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Mayank MamtaniB. Riley Securities, Inc.
Ilya ZubkovFreedom Broker